ByJohn A
Noom Med vs GLP-1 Telehealth: Which Fits You?
Noom Med fits people who want daily behavioral coaching wrapped around a prescription, while standalone GLP-1 telehealth fits people who mostly want the medication, refills, and clinical follow-up without a full curriculum. The two are not really the same product. One is a coaching app that added prescribing; the other is a prescribing service that treats coaching as optional. The right pick depends on whether you value structure or want to keep things lean.
What is the actual difference between the two models?
Noom started as a behavior-change app built on food logging, psychology lessons, and human coaches. Noom Med is the medication arm layered on top, aimed at people who qualify for a GLP-1 and want the app’s structure alongside it. Most standalone GLP-1 telehealth services run the opposite way. They begin with an intake, a clinician, and a prescription, and any coaching is a light add-on rather than the reason the product exists.
That difference shapes everything downstream: what you pay, what you get for the money, and what happens when supply tightens or your dose needs to change. Reading old Noom reviews will tell you about the app’s habit-tracking and its subscription billing, but it will say little about the medication side, because that arm is newer and works differently.
What are Noom reviews actually describing?
This is worth separating cleanly. The bulk of published Noom reviews cover the coaching subscription: the daily lessons, the color-coded food system, and the auto-renewing charge that has generated a steady stream of complaints. Those reviews are informative about the app, but they are close to useless for judging Noom Med. Someone weighing the medication arm needs to know about prescribing access, whether the drug is a brand or compounded, and what the combined monthly cost looks like. The coaching reputation does not answer any of that.
So take the star ratings with context. A person frustrated by a renewal charge and a person deciding between GLP-1 platforms are asking different questions.
How do the two compare on the things that matter?
| Factor | Noom Med | Standalone GLP-1 telehealth |
|---|---|---|
| Core product | Behavior coaching plus prescribing arm | Prescribing, refills, follow-up |
| What you pay for | Subscription and coaching, plus medication | Mostly the visit and the medication |
| Coaching depth | Structured daily curriculum | Usually light or optional |
| Medication type | Brand where accessible | Brand or compounded, varies by service |
| Best fit | Wants structure with the drug | Wants a clean prescribing pathway |
Does the coaching actually change outcomes?
The guideline evidence is honest about this: medication drives most of the weight change in modern obesity treatment, and behavioral support helps people stay on it and manage side effects. The 2025 clinical practice guideline update on pharmacotherapy for obesity treats drug therapy as the primary lever for people who qualify, with lifestyle support as the frame around it (guideline). The AGA guideline on pharmacological interventions reaches a similar conclusion, recommending medication alongside lifestyle change rather than as a substitute for it (AGA guideline).
So coaching is not decorative, but it is not the engine either. If you already have habits you trust, paying a premium for a daily curriculum may not be worth it. If accountability is your weak point, the structure can be the difference between staying on treatment and quitting at the first wave of nausea.
What is the mechanism you are paying to access?
Both models exist because GLP-1 receptor agonists work. These drugs slow gastric emptying and act on appetite signaling, and the dual GIP and GLP-1 agents extend that effect further; the pharmacology is well described (mechanism review, tirzepatide discovery). The category is also shifting toward oral options. Orforglipron, a daily oral small-molecule GLP-1 agonist, moved from early trials (phase 2) through later data (obesity trial) to FDA approval, marketed as FOUNDAYO (first approval). An oral option could eventually change which telehealth model makes sense, since a pill removes some of the friction that coaching apps use to justify their subscriptions.
Where does compounded medication fit, and where can you compare prices?
When brand supply is tight or coverage is denied, some telehealth services offer compounded semaglutide or tirzepatide. This matters for cost comparisons, because compounded pricing is often a flat monthly cash figure with no insurance involved. It also carries a real caveat: compounded medication is prepared by a compounding pharmacy and is not an FDA-approved product, so it has not been through the process behind the published trial evidence.
If you are pricing options, it helps to see the models side by side rather than through app-store ratings. The named field of GLP-1 telehealth includes Ro, Hims and Hers, Henry Meds, LillyDirect, and NovoCare, and independent breakdowns such as formblends.com lay out flat pricing and prescribing details for physician-supervised routes. Compare the sustainable monthly total, not the introductory month, and confirm whether coaching is bundled or billed separately.
Who should think twice about either one?
People with metabolic conditions have more at stake than a subscription fee. Someone with metabolic dysfunction-associated steatotic liver disease, for example, should have treatment coordinated with the guidance for that condition rather than run through a generic weight app (MASLD guidelines). And the clinical definition of obesity itself has been refined to distinguish body composition from disease-level impairment (diagnostic criteria), which affects who genuinely benefits from medication versus who is chasing a number on a scale. Neither telehealth model replaces that judgment.
Key takeaways
- Noom Med is a coaching app with a prescribing arm; most GLP-1 telehealth is prescribing first.
- Older Noom reviews describe the app, not the medication side, so weight them accordingly.
- Medication drives most of the outcome; coaching mainly helps adherence.
- Compounded options are cheaper and cash-based but are not FDA-approved products.
See also: Oxytocin Nasal Spray for Your Sex Life: I Read the Studies So You Don’t Have To
Frequently asked questions
Is Noom Med a weight-loss drug program or a coaching app?
It is a coaching app with a medication arm bolted on. The behavioral program came first, and Noom Med adds a prescribing pathway for people who qualify. Standalone GLP-1 telehealth services usually start from the medication and treat coaching as optional.
Do Noom reviews reflect the medication side or the app?
Most Noom reviews describe the coaching app and its subscription billing, not the medication arm. That matters because someone judging Noom Med needs to know about prescribing access, drug supply, and cost, which older app reviews rarely cover.
Can either model prescribe brand GLP-1 medication?
Both can prescribe when a patient qualifies clinically, but access depends on supply and insurance rather than the platform. Some telehealth services also offer compounded medication, which is not an FDA-approved product.
Is compounded semaglutide the same as Wegovy?
No. Compounded medication is prepared by a compounding pharmacy and has not gone through FDA approval. It may contain the same active molecule as a brand product, but it is not the same regulated drug.
Which model fits someone who wants structure?
Noom Med fits people who want daily behavioral structure alongside a prescription. A leaner GLP-1 telehealth service fits people who mainly want prescribing, refills, and follow-up without a full coaching curriculum.
